Zoetis Inc. (NYSE:ZTS) Stake Lifted by Personal CFO Solutions LLC


Share on StockTwits

Personal CFO Solutions LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,647 shares of the company’s stock after buying an additional 548 shares during the quarter. Personal CFO Solutions LLC’s holdings in Zoetis were worth $1,762,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. FMR LLC grew its stake in Zoetis by 27.4% during the 4th quarter. FMR LLC now owns 14,036,704 shares of the company’s stock worth $2,323,075,000 after buying an additional 3,017,046 shares during the last quarter. Alliancebernstein L.P. grew its stake in Zoetis by 9.1% during the 4th quarter. Alliancebernstein L.P. now owns 16,645,263 shares of the company’s stock worth $2,754,791,000 after buying an additional 1,386,823 shares during the last quarter. BlackRock Inc. grew its stake in Zoetis by 3.3% during the 4th quarter. BlackRock Inc. now owns 40,720,915 shares of the company’s stock worth $6,739,311,000 after buying an additional 1,291,599 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in Zoetis by 72.9% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,917,253 shares of the company’s stock worth $317,056,000 after buying an additional 808,118 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its position in Zoetis by 46.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,065,356 shares of the company’s stock worth $176,317,000 after acquiring an additional 339,137 shares during the period. Hedge funds and other institutional investors own 92.50% of the company’s stock.

ZTS stock traded down $0.04 during mid-day trading on Tuesday, hitting $160.12. The stock had a trading volume of 20,665 shares, compared to its average volume of 1,908,971. The company has a current ratio of 3.47, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41. Zoetis Inc. has a 1-year low of $90.14 and a 1-year high of $176.64. The company has a fifty day moving average of $162.26 and a 200 day moving average of $161.71. The stock has a market capitalization of $76.08 billion, a price-to-earnings ratio of 47.53, a PEG ratio of 4.35 and a beta of 0.71.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 16th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.05. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. During the same period last year, the company posted $0.92 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 3.63 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 1st. Shareholders of record on Wednesday, April 21st will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 0.62%. The ex-dividend date is Tuesday, April 20th. Zoetis’s payout ratio is currently 27.47%.

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on Zoetis from $167.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, November 13th. Credit Suisse Group boosted their price target on Zoetis from $197.00 to $203.00 in a research report on Wednesday, February 17th. Truist boosted their price target on Zoetis from $160.00 to $170.00 in a research report on Thursday, November 12th. Finally, Barclays upped their price objective on Zoetis from $175.00 to $189.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus target price of $167.25.

In other news, EVP Robert Edward Kelly sold 2,054 shares of the stock in a transaction dated Thursday, February 11th. The stock was sold at an average price of $161.15, for a total transaction of $331,002.10. Following the transaction, the executive vice president now owns 10,029 shares of the company’s stock, valued at approximately $1,616,173.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kristin C. Peck sold 10,500 shares of the stock in a transaction dated Wednesday, November 25th. The shares were sold at an average price of $161.51, for a total value of $1,695,855.00. Following the transaction, the chief executive officer now directly owns 38,374 shares in the company, valued at approximately $6,197,784.74. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,734 shares of company stock worth $2,217,592. Insiders own 0.17% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What is a conference call?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.